Mangoceuticals, Inc. (NASDAQ:MGRX) is a company focused on developing, marketing, and selling a variety of men’s health and wellness products and services via a secure telemedicine platform. To date, the Company has identified men’s wellness telemedicine services and products as a growing sector and especially related to the area of erectile dysfunction (ED). The Company has developed a new brand of ED product under the brand name “Mango” (think “Man Go”). For more information, please visit www.MangoRx.com.
Created using a special formulation featuring the same active ingredient as in Cialis (Tadalafil), each part of the Mango formulation plays a critical role in helping men achieve optimum performance. We believe the key to our success lies in our unique blend of ingredients, which are used in U.S. Food and Drug Administration (“FDA”) approved drugs. Mango contains a combination of Tadalafil, Oxytocin, and L-Arginine that have been traditionally used to treat sexual dysfunction.
Mango is a prescription medication that must be approved by a physician. After an individual has completed an online telehealth visit, our network of medical providers will review and approve a prescription if medically appropriate. Mango is a rapidly dissolved tablet (RDT) that is absorbed orally. For best results, we advise taking Mango at least 15 minutes before engaging in sexual activity. Tadalafil, one of the main ingredients in Mango, typically has effects that last up to 36 hours.
News Alert: Mangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” Podcast
MGRX has been engaged as a new sponsor for Barstool Sports’ “Only Stans” podcast (barstoolsports.com/shows/39956939/only-stans).
“We couldn’t be more excited to have the opportunity to sponsor the hugely popular Only Stans podcast,” stated MGRX Co-Founder and CEO, Jacob Cohen. “It isn’t easy to find, land, and execute a sponsorship this on-target from a branding perspective. This is a wildly popular podcast with a massive audience that resonates especially well with our target market. And we are thrilled to have access to that audience to help them truly appreciate our product benefits.”
The Only Stans podcast, “the world’s first Only Fans show by the world’s first Only Fans journalist”, averages more than 320,000 listeners per episode. The Company plans on sponsoring at least 8 episodes over the next two months, with more brand involvement potentially in the works. Company representatives believe this strategy has the potential to generate substantial new interest among both customers and prospective investors.
“The idea here is simple,” added Cohen. “We are aligning ourselves with BarStool Sports, which is a nationally recognized brand that has a rock-solid track record in terms of appealing to a male audience and has a massive market footprint and overall audience size. Through that process, we are sponsoring the ‘Only Stans’ podcast, which appeals to our sexually active target audience. And we also want our shareholders to know that we are serious about growth-oriented marketing, and we will be aggressively hunting additional sponsorship deals with similar media opportunities in the future on Barstool as well as other similar platforms.”
Back in March, 2023, MGRX announced the closing of its initial public offering of 1,250,000 shares of common stock at a public offering price of $4.00 per share. The total gross proceeds of the offering were $5,000,000, prior to deducting underwriting discounts and commissions and other offering expenses payable by the Company. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 187,500 shares of its common stock at the public offering price of $4.00 per share, less the underwriting discounts and commissions.The Company intends to use the net proceeds from the offering to finance the marketing and operational expenses associated with the planned marketing of its Mango ED product, to hire additional personnel to build organizational talent, to develop and maintain software, and for working capital and other general corporate purposes.
MangoRx’s common stock began trading on The Nasdaq Capital Market on March 21, 2023 under the symbol “MGRX.”
Since our alert today morning, MGRX is already up over 9% and counting. This could just be the beginning for the stock to the upside considering the public offering was priced at $4 per share. As always, conduct your own DD and follow traders vigilance.
Disclaimer: Please ensure to fully read and comprehend our disclaimer found at https://investorbrandmedia.com/disclaimer/. A payment of $4,500 was received by InvestorBrandMedia.com from Bullyzeye Media LLC for content distribution on MGRX, from 06/12/2023 to 07/07/2023. InvestorBrandMedia.com is neither an investment advisor nor a registered broker. No current owner, employee, or independent contractor of InvestorBrandMedia.com is registered as a securities broker-dealer, broker, investment advisor, or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
This article may contain forward-looking statements as defined under Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. These statements, often incorporating terms like “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or similar expressions about future performance or conduct, are based on present expectations, estimates, and projections, and are not historical facts. They carry various risks and uncertainties that may result in significant deviation from the anticipated results or events. Past performance does not guarantee future results.
InvestorBrandMedia.com does not commit to updating forward-looking statements based on new information or future events. Readers are encouraged to review all public SEC filings made by the profiled companies at https://www.sec.gov/edgar/searchedgar/companysearch. It is always important to conduct thorough due diligence and exercise caution in trading.
InvestorBrandMedia.com is not managed by a licensed broker, a dealer, or a registered investment adviser. The content here is purely informational and should not be taken as investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor regarding forward-looking statements. Any statement that projects, foresees, expects, anticipates, estimates, believes, or understands certain actions to possibly occur are not historical facts and may be forward-looking statements. These statements are based on expectations, estimates, and projections that could cause actual results to differ greatly from those anticipated.
Investing in micro-cap and growth securities is speculative and entails a high degree of risk, potentially leading to a total or substantial loss of investment. Please note that no content published here constitutes a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer or solicitation by InvestorBrandMedia.com or any third-party service provider to buy or sell securities or other financial instruments. The content in this article does not address the circumstances of any specific individual or entity and does not constitute professional and/or financial advice. InvestorBrandMedia.com is not a fiduciary by virtue of any person’s use of or access to this content.